Daily Stock Analysis, CBRE, CHINA BIOLOGIC PRODUCTS INC, priceseries

CHINA BIOLOGIC PRODUCTS INC. Daily Stock Analysis
Stock Information
Open
97.26
Close
97.29
High
98.21
Low
96.95
Previous Close
97.41
Daily Price Gain
-0.12
YTD High
99.73
YTD High Date
Sep 10, 2021
YTD Low
58.73
YTD Low Date
Jan 5, 2021
YTD Price Change
37.79
YTD Gain
63.51%
52 Week High
99.73
52 Week High Date
Sep 10, 2021
52 Week Low
43.17
52 Week Low Date
Oct 28, 2020
52 Week Price Change
48.81
52 Week Gain
100.68%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 9. 2017
31.57
Mar 13. 2017
36.03
21 Trading Days
14.12%
Link
LONG
Nov 3. 2017
39.90
Dec 1. 2017
42.12
19 Trading Days
5.57%
Link
LONG
Oct 30. 2018
40.12
Nov 20. 2018
42.48
15 Trading Days
5.89%
Link
LONG
Jan 7. 2019
40.01
Feb 27. 2019
49.73
35 Trading Days
24.29%
Link
LONG
Dec 4. 2019
57.03
Jan 6. 2020
60.27
21 Trading Days
5.68%
Link
LONG
Apr 6. 2020
39.78
Apr 20. 2020
42.57
9 Trading Days
7.01%
Link
LONG
May 20. 2020
39.60
Jun 11. 2020
48.50
15 Trading Days
22.47%
Link
LONG
Nov 4. 2020
51.99
Dec 17. 2020
64.40
30 Trading Days
23.87%
Link
LONG
Feb 2. 2021
65.44
Mar 5. 2021
74.82
22 Trading Days
14.33%
Link
LONG
Jul 21. 2021
85.96
Aug 12. 2021
95.62
16 Trading Days
11.24%
Link
Company Information
Stock Symbol
CBRE
Exchange
NasdaqGS
Company URL
http://www.chinabiologic.com
Company Phone
86-10-6598-3111
CEO
Xiao Ying Gao
Headquarters
-
Business Address
18TH FL, JIALONG INTERNATIONALBUILDING, 19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT, BEIJING, CHINA 100125
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001369868
About

China Biologic Products, Inc. operates as a biopharmaceutical company, which engages in the manufacture and distribution of plasma-based pharmaceutical products and other biological substances. Its products include human albumin, human immunoglobulin for intravenous injection, human Hepatitis B immunoglobulin, human rabies immunoglobulin, human immunoglobulin, human coagulation factor VIII, human prothrombin complex concentrate, and placenta polypeptide. The company was founded on December 20, 1989 and is headquartered in Beijing, China.

Description

China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing human hepatitis B immunoglobulin (pH4) for intravenous injection; human fibrinogen; immune globulin intravenous; human antithrombin III; human cytomegalovirus immunoglobulin; human coagulation factor IX; and human fibrin sealant products. The company sells its products directly, as well as through distributors. China Biologic Products, Inc. is headquartered in Beijing, the People's Republic of China.